248 related articles for article (PubMed ID: 18549935)
1. Prognostic significance of pleural fluid data in patients with malignant effusion.
Bielsa S; Salud A; Martínez M; Esquerda A; Martín A; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2008 Jul; 19(5):334-9. PubMed ID: 18549935
[TBL] [Abstract][Full Text] [Related]
2. Predictors of mortality within three months in the patients with malignant pleural effusion.
Ozyurtkan MO; Balci AE; Cakmak M
Eur J Intern Med; 2010 Feb; 21(1):30-4. PubMed ID: 20122610
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.
Hiraki A; Aoe K; Murakami T; Nakamura Y; Yamazaki K; Sueoka N; Taguchi K; Kamei T; Maeda T; Takeyama H; Kishimoto T; Nishimura M; Sugi K
Oncol Rep; 2005 Aug; 14(2):357-62. PubMed ID: 16012715
[TBL] [Abstract][Full Text] [Related]
4. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.
Bielsa S; Esquerda A; Salud A; Montes A; Arellano E; Rodríguez-Panadero F; Porcel JM
Eur J Intern Med; 2009 Jul; 20(4):383-6. PubMed ID: 19524179
[TBL] [Abstract][Full Text] [Related]
5. Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients.
Aoe K; Hiraki A; Yamazaki K; Nakamura Y; Murakami T; Maeda T; Nishimura M; Sugi K; Ueoka H
Int J Oncol; 2006 Jul; 29(1):65-72. PubMed ID: 16773186
[TBL] [Abstract][Full Text] [Related]
6. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion.
Chierakul N; Kanitsap A; Chaiprasert A; Viriyataveekul R
Respirology; 2004 Mar; 9(1):66-9. PubMed ID: 14982604
[TBL] [Abstract][Full Text] [Related]
7. [Tetracycline pleurodesis for treatment of malignant pleural effusions. Retrospective study of 91 cases].
Martínez Moragón E; Aparicio Urtasun J; Sanchis Aldás J; Fullana Monllor J; Sanchis Moret F; Montalar Salcedo J; Marco Martínez V
Med Clin (Barc); 1993 Jul; 101(6):201-4. PubMed ID: 8332018
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic implications of pleural adhesions in malignant effusions.
Bielsa S; Martín-Juan J; Porcel JM; Rodríguez-Panadero F
J Thorac Oncol; 2008 Nov; 3(11):1251-6. PubMed ID: 18978559
[TBL] [Abstract][Full Text] [Related]
9. Important prognostic factors for survival in patients with malignant pleural effusion.
Zamboni MM; da Silva CT; Baretta R; Cunha ET; Cardoso GP
BMC Pulm Med; 2015 Mar; 15():29. PubMed ID: 25887349
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and soluble intercellular adhesion molecule-1 in lung adenocarcinoma with malignant pleural effusion: correlations with patient survival and pleural effusion control.
Qian Q; Zhan P; Sun WK; Zhang Y; Song Y; Yu LK
Neoplasma; 2012; 59(4):433-9. PubMed ID: 22489699
[TBL] [Abstract][Full Text] [Related]
11. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
12. [Influence of thoracentesis and pleural biopsy on biochemical parameters and cytology of pleural fluid].
Haro-Estarriol M; Alvarez-Castillo LA; Baldó-Padró X; Ramírez-Malagón JM; Rubio-Goday M; Sendra-Salillas S
Arch Bronconeumol; 2007 May; 43(5):277-82. PubMed ID: 17519139
[TBL] [Abstract][Full Text] [Related]
13. [Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa].
Baur M; Schlappack O; Jakesz R; Dittrich C
Wien Klin Wochenschr; 1992; 104(23):714-6. PubMed ID: 1475980
[TBL] [Abstract][Full Text] [Related]
14. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
Elia S; Massoud R; Guggino G; Cristino B; Cortese C; De Massimi AR; Zenobi R
Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of pleural effusion caused by lung carcinoma with circular intrapleural hyperthermic perfusion and its mechanism].
Kang M; Zhou L; Lin P
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1176-9. PubMed ID: 11769704
[TBL] [Abstract][Full Text] [Related]
17. [Comparative analysis of Light's criteria and other biochemical parameters to distinguish exudates from transudates].
Jiménez Castro D; Díaz Nuevo G; Pérez-Rodríguez E
Rev Clin Esp; 2002 Jan; 202(1):3-6. PubMed ID: 11940425
[TBL] [Abstract][Full Text] [Related]
18. Bedside talc pleurodesis for malignant pleural effusion: factors affecting success.
Aydogmus U; Ozdemir S; Cansever L; Sonmezoglu Y; Kocaturk CI; Bedirhan MA
Ann Surg Oncol; 2009 Mar; 16(3):745-50. PubMed ID: 19116753
[TBL] [Abstract][Full Text] [Related]
19. Etiology and prognostic significance of massive pleural effusions.
Jiménez D; Díaz G; Gil D; Cicero A; Pérez-Rodríguez E; Sueiro A; Light RW
Respir Med; 2005 Sep; 99(9):1183-7. PubMed ID: 16085221
[TBL] [Abstract][Full Text] [Related]
20. [Role of c-c chemokines in the determination of pleural effusion etiology].
Trzaska-Sobczak M; Pierzchała W; Brozek G; Farnik M
Wiad Lek; 2008; 61(7-9):190-4. PubMed ID: 19172830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
